

DLL4 Antibody



Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 75-80	Source/Isotype: Rabbit	UniProt ID: #Q9NR61	Entrez-Gene Id: 54567
-------------------------------	-------------------------	-----------------------------------	---------------------------	----------------------------------	-------------------------------	---------------------------------

Product Usage Information

Application

Western Blotting
Immunoprecipitation

Dilution

1:1000
1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

Specificity/Sensitivity

DLL4 Antibody detects endogenous levels of total DLL4 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to a region surrounding residue Leu617 of human DLL4. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Notch signaling is activated upon engagement of the Notch receptor with its ligands, the DSL (Delta, Serrate, Lag2) proteins of single-pass type I membrane proteins. The DSL proteins contain multiple EGF-like repeats and a DSL domain that is required for binding to Notch (1,2). Five DSL proteins have been identified in mammals: Jagged1, Jagged2, Delta-like (DLL) 1, 3 and 4 (3). Ligand binding to the Notch receptor results in two sequential proteolytic cleavages of the receptor by the ADAM protease and the γ -secretase complex. The intracellular domain of Notch is released and then translocates to the nucleus where it activates transcription. Notch ligands may also be processed in a way similar to Notch, suggesting a bi-directional signaling through receptor-ligand interactions (4-6). DLL4 expression is highly restricted to the vascular endothelium (7), and haploinsufficiency of DLL4 results in major defects in vascular systems in mouse (8-11). Blockade of DLL4 inhibits tumor growth in model systems (12-14).

Background References

1. Wilson, A. and Radtke, F. (2006) *FEBS Lett.* 580, 2860-2868.
2. Hansson, E.M. et al. (2004) *Semin. Cancer Biol.* 14, 320-328.
3. Chiba, S. (2006) *Stem Cells* 24, 2437-2447.
4. Bland, C.E. et al. (2003) *J. Biol. Chem.* 278, 13607-13610.
5. Six, E. et al. (2003) *Proc. Natl. Acad. Sci. USA* 100, 7638-7643.
6. LaVoie, M.J. and Selkoe, D.J. (2003) *J. Biol. Chem.* 278, 34427-34437.
7. Shutter, J.R. et al. (2000) *Genes Dev.* 14, 1313-1318.
8. Gale, N.W. et al. (2004) *Proc. Natl. Acad. Sci. USA* 101, 15949-15954.
9. Krebs, L.T. et al. (2004) *Genes Dev.* 18, 2469-2473.
10. Duarte, A. et al. (2004) *Genes Dev.* 18, 2474-2478.
11. Hellström, M. et al. (2007) *Nature* 445, 776-780.
12. Noguera-Troise, I. et al. (2006) *Nature* 444, 1032-1037.
13. Lobov, I.B. et al. (2007) *Proc. Natl. Acad. Sci. USA* 104, 3219-3224.
14. Scheinet, J.S. et al. (2007) *Blood* 109, 4753-4760.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween@ 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.